Akademik Veri Yönetim Sistemi
Asian Journal of Surgery, 2026 (SCI-Expanded, Scopus)
Aim/backgroundGastric balloon application is a common method in obesity management, but early removal remains a challenge. This study aimed to evaluate whether gastric botox (BTX-A) affects balloon tolerance and weight loss.MethodsA randomized controlled trial was conducted at a tertiary university hospital between January and December 2024. Patients meeting obesity criteria were enrolled and completed the S-36 quality of life questionnaire. They were randomized 1:1 into two groups: the control group received only a 500 cc gastric balloon, while the study group received 200 UI BTX-A, followed by balloon placement after seven days. Rhodex scores were assessed at the 1st hour, 1st day, and 7th day post-insertion. After balloon removal, the S-36 form was repeated. Early balloon removal rates and weight loss after six months were compared.ResultsA total of 140 patients were randomized; however, 10 patients were excluded due to predefined criteria, and ultimately 130 patients were evaluated. Early balloon removal occurred in 4 patients in the control group and 2 in the study group (p = 0.681). While initial Rhodex scores were similar, scores on the 1st and 7th days were significantly lower in the study group (p < 0.001). Readmissions occurred in 9 control and 3 study patients (9.2% total). Quality of life improved in both groups without significant differences. Six-month weight loss was 14.2 kg (study) vs. 14.5 kg (control) (p = 0.865).ConclusionBTX-A reduced early balloon removal and hospital readmissions clinically but not statistically. It did not affect weight loss or quality of life.Registration numberNCT05872932